Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices
The Analyst, 2026
Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis
JAMA pediatrics, 2026
Residual gastric content after tirzepatide discontinuation: is one week enough?
Minerva anestesiologica, 2026
LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis
International journal of obesity (2005), 2026
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Diabetes, obesity & metabolism, 2026
GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights from a Pilot Implementation Program
Canadian journal of diabetes, 2026
Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells
Circulation, 2026;153(25):2110-2113
Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction
Journal of clinical medicine, 2026;15(12)
Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review
International journal of molecular sciences, 2026;27(12)
Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases
Drug metabolism and disposition: the biological fate of chemicals, 2026;54(8):100346
Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome
Frontiers in immunology, 2026;17:1849387
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence
Cureus, 2026;18(6):e111322
Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024
Acta psychiatrica Scandinavica, 2026
Short- and Long-term Effects of Semaglutide 2.4 mg on Energy Intake, Appetite, and Food Reward: A 60-week, Double-Blind Randomized Controlled Trial
The American journal of clinical nutrition, 2026;:101403
Long-term effects of weight-reducing drugs in people with hypertension
The Cochrane database of systematic reviews, 2026;6:CD007654
Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals
Cardiovascular diabetology. Endocrinology reports, 2026;12(1)
Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs)
International journal of obesity (2005), 2026
Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection
ACG case reports journal, 2026;13(6):e02168
Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence
Journal of clinical medicine, 2026;15(12)